SMC^® Human GFAP High Sensitivity Immunoassay Kit

SMC is a registered trademark of Singulex

SMCxPRO is a registered trademark of Merck KGaA, Darmstadt, Germany

FEMTOQUEST is a trademark of Merck KGaA, Darmstadt, Germany

• Sensitivity: LLOQ 230 fg/mL* (SMCxPRO^® Instrument)
• Standard Curve Range: 60-300,000 fg/mL
• Intra-assay CV: <15%
• Inter-assay CV: <20%
• Linearity: Serum: 101% Plasma: 99% CSF: 101%
• Recovery: Serum: 118% Plasma: 115% CSF: 101%

*Indicative LLOQ created from average of 14 independent in house runs, where >80% met same value defined with CV & Recovery +/- 20%. Refer to CoA for lot specific performance.

NeuroscienceNeurological DisordersNeurodegenerative DiseasesNeuroinflammation

Alzheimer′s Disease / Aging / Nervous System / Neurodegenerative Diseases / Neurofilament & Neuron Metabolism / Neuronal & Glial Markers / Neurodegenerative Medicine / Neuroscience

Although GFAP was detectable in non-human primate (rhesus macaque and cynomolgus monkey), feline, rat, mouse, and canine samples, the assay has not been verified for these species.

Our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Glial fibrillary acidic protein (GFAP) is a key intermediate filament protein predominantly expressed in astrocytes, a type of glial cell in the central nervous system. GFAP plays a vital role in maintaining the structural integrity of astrocytes and supporting their functions, including the regulation of the extracellular environment, the provision of metabolic support to neurons, and the modulation of synaptic activity.

GFAP serves as an important biomarker for astrocyte activation and neuroinflammation. Elevated levels of GFAP in cerebrospinal fluid (CSF) and blood may indicate reactive astrogliosis, a condition often associated with brain injury, multiple sclerosis, Alzheimer′s disease, and other neurodegenerative disorders. As increased GFAP levels often reflect the extent of neuroinflammatory responses and neuronal damage, GFAP is a critical target to monitor when developing strategies aimed at mitigating neuroinflammation and preserving neuronal health.

96 well assay